These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27918714)

  • 1. Reply to A. Wang-Gillam et al.
    Sohal DP; Mangu PB; Laheru D; Khorana AA
    J Clin Oncol; 2017 Feb; 35(6):690-691. PubMed ID: 27918714
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
    Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
    Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats.
    Barth SW; Briviba K; Watzl B; Jäger N; Marko D; Esselen M
    Biotechnol J; 2010 Mar; 5(3):321-7. PubMed ID: 20213647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
    Kümler I; Balslev E; Stenvang J; Brünner N; Nielsen D
    BMC Cancer; 2015 Feb; 15():78. PubMed ID: 25885574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
    Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
    Meisenberg C; Ashour ME; El-Shafie L; Liao C; Hodgson A; Pilborough A; Khurram SA; Downs JA; Ward SE; El-Khamisy SF
    Nucleic Acids Res; 2017 Feb; 45(3):1159-1176. PubMed ID: 28180300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan in cervical cancer.
    Kavanagh JJ; Verschraegen CF; Kudelka AP
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):94-8. PubMed ID: 9726099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
    Eder JP; Chan V; Wong J; Wong YW; Ara G; Northey D; Rizvi N; Teicher BA
    Cancer Chemother Pharmacol; 1998; 42(4):327-35. PubMed ID: 9744779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan and radiation in combined-modality therapy for solid tumors.
    Choy H; MacRae R
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):22-8. PubMed ID: 11497228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan in epithelial ovarian cancer.
    Gershenson DM
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):29-31. PubMed ID: 12109803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
    Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
    Bonneterre J
    Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
    Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
    Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan (Campto) in the treatment of pancreatic cancer.
    Pizzolato JF; Saltz LB
    Expert Rev Anticancer Ther; 2003 Oct; 3(5):587-93. PubMed ID: 14599083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
    Cunningham D; Glimelius B
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
    Cunningham D
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan for the treatment of cervical cancer.
    Verschraegen CF
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):32-4. PubMed ID: 12109804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of experimental pancreatic cancer by doxorubicin-, mitoxantrone-, and irinotecan-drug eluting beads.
    Yagublu V; Caliskan N; Lewis AL; Jesenofsky R; Gasimova L; Löhr JM; Keese M
    Pancreatology; 2013; 13(1):79-87. PubMed ID: 23395574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.